シスプラチンエピルビシンリピオドール懸濁液(CELE)による肝細胞癌動注療法における有用性.

概要

論文の詳細を見る
To obtain a more possible effect against hepatocellular carcinoma (HCC), and gradually-releasing of cisplatin and epirubicin, we have tried to develop a new cisplatin-epirubicin-lipiodol suspension (CELS), using phosphatidylcholine as a coupling agent. Cisplatin and epirubicin were gradually released from CELS <I>in vitro</I> and passed gradually into systemic circulation after injection hepatic artery <I>in vivo</I>. Ten patients with HCC were treated with CELS therapy. Immediately, serum alpha-fetoprotein (AFP) and abnormal prothrornbin (PIVKA-II) levels were decreased. On most of 10 patients, no fatal side effects were observed. No survival ratio was estimated because of short term prognosis. It seems that the combination therapy with transcatheter arterial embolization (TAE) was more effective. This result suggests that CELS accumulates in the carcinoma tissue, and gradually releases the two drugs. It concludes that GELS therapy in safe and more effective compared with cisplatin suspended in lipiodol therapy for HCC.
日本DDS学会の論文